ArticleBioengineering & translational medicine2025
Carboxymethyl cellulose-polylactic acid particles for inhibiting anoikis and enhancing wound healing efficacy of human mesenchymal stem cells.
Article in Bioengineering & translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Carboxymethyl cellulose-polylactic acid particles for inhibiting anoikis and enhancing wound healing efficacy of human mesenchymal stem cells.Bioengineering & translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult human mesenchymal stem cells (hMSCs) injection into the wound site promotes angiogenesis and the wound-closing process by secreting various growth and immune-modulating factors. However, lower cell attachment sites and the hypoxic microenvironment in the wound site limit their viability and engraftment rate, leading to programmed cell death, anoikis. We synthesized carboxymethyl cellulose-coated polylactic acid (CMC-PLA) particles to prevent anoikis by providing an attachable surface for hMSCs. In vitro experiments demonstrated enhanced viability and secretion of growth factors by hMSCs under severely hypoxic microenvironments, when CMC-PLA particles provided attachment surfaces, compared to controls. Furthermore, in vivo experiments showed that CMC-PLA particles injected with hMSCs improved collagen synthesis and wound closure more than those of the control groups. These findings suggest that CMC-PLA particles effectively enhance the therapeutic potential of hMSCs by providing a supportive microenvironment, promoting cell survival, proliferation, and angiogenesis, thereby offering a promising approach for advanced wound healing therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.